The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.
Number 1: Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for ...
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback